Clinical trial
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on…
NCT00157092 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00157092 |
|---|---|
| Title | Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency |
| Official title | A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Collaborators | Arriva Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Alpha1-antitrypsin Deficiency |
| Intervention type | Drug |
| Interventions | Aerosolized, Recombinant Alpha 1-Antitrypsin |
| Enrollment | 15 |
| Start date | Mar 1, 2004 |
| Primary completion | Oct 14, 2004 |
| Completion | Oct 14, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | May 5, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: